highly significantP < .001
According to a recent follow-up analysis after 3 years, MP + bortezomib has a highly significant impact on improved OS (HR, 0.653; P < .001), with an associated 35% reduction in risk of death.
According to a recent follow-up analysis after 3 years, MP + bortezomib has a highly significant impact on improved OS (HR, 0.653; P < .001), with an associated 35% reduction in risk of death.